Table 1.
Summary of published cases using immunomodulatory agents for suppression/eradication of refractory inhibitors in hemophilia
*Aleem et al. used rituximab as a single-agent first-line therapy.
Summary of published cases using immunomodulatory agents for suppression/eradication of refractory inhibitors in hemophilia
*Aleem et al. used rituximab as a single-agent first-line therapy.
